Dr Sarah Diermeier is a pioneer in exploring the use of long non-coding RNA molecules to target cancer treatment.
She’s the founder and chief scientific officer of Amaroq Therapeutics, a biotech company focused on developing a new class of therapeutics to treat cancer.
The University of Otago
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
